-

Foundation Medicine Appoints Ritesh Khullar as Chief Commercial Officer

Oncology industry veteran to lead product sales and operations efforts

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Foundation Medicine, Inc. today announced the appointment of Ritesh (Tesh) Khullar as its chief commercial officer, effective January 20, 2020. Mr. Khullar joins Foundation Medicine from Flatiron Health, where he was responsible for leading and scaling provider service offerings. With more than two decades of experience working in oncology, Mr. Khullar brings deep expertise in strategic commercialization to drive business growth, as well as experience accelerating market development, both of which will support the Company’s position as a leader in comprehensive genomic profiling.

“With Mr. Khullar’s proven expertise in customer engagement and operational excellence, his leadership at Foundation Medicine will enable continued advancement of patient access to precision medicine through comprehensive genomic profiling,” said Cindy Perettie, chief executive officer at Foundation Medicine. “He also brings great passion for creating patient-focused solutions, which is core to our mission at Foundation Medicine.”

Mr. Khullar also shared, “I am excited to join Foundation Medicine where my relationships with the provider network, particularly in community oncology practices, can bring new insights to the process of navigating the cancer care continuum as we work together to advance our patient-centric solutions for physicians and patients.”

At Flatiron Health, Mr. Khullar was instrumental in growing the team across Flatiron Health’s commercial division, including sales, professional services, customer success, and product operations.

Prior to Flatiron Health, Mr. Khullar served as the national vice president and general manager of sales and account management for McKesson Specialty Health. He also held roles of increasing responsibility at Oncology Therapeutics Network (OTN), where he led the formation of two oncology group purchasing organizations: National Oncology Alliance and Onmark.

Mr. Khullar holds a Master of Business Administration from the University of San Francisco and a Bachelor of Arts in history with a minor in computer science and engineering, political science, and law and society from the University of California, San Diego.

About Foundation Medicine

Foundation Medicine is a molecular information company dedicated to a transformation in cancer care in which treatment is informed by a deep understanding of the genomic changes that contribute to each patient's unique cancer. The company offers a full suite of comprehensive genomic profiling assays to identify the molecular alterations in a patient’s cancer and match them with relevant targeted therapies, immunotherapies and clinical trials. Foundation Medicine’s molecular information platform aims to improve day-to-day care for patients by serving the needs of clinicians, academic researchers and drug developers to help advance the science of molecular medicine in cancer. For more information, please visit www.FoundationMedicine.com or follow Foundation Medicine on Twitter (@FoundationATCG).

Foundation Medicine® is a registered trademark of Foundation Medicine, Inc.

Contacts

Media:
Lee-Ann Murphy, 617-245-3077
pr@foundationmedicine.com

Foundation Medicine


Release Versions

Contacts

Media:
Lee-Ann Murphy, 617-245-3077
pr@foundationmedicine.com

More News From Foundation Medicine

Foundation Medicine to Launch FoundationOne®PGx, a Pharmacogenetic Offering, Through Expanded Partnership with Fulgent Genetics

BOSTON & EL MONTE, Calif.--(BUSINESS WIRE)--FoundationOne®PGx helps guide cancer therapy selection and dosing strategies to support safer, more effective patient care...

Foundation Medicine Expands Existing Collaboration with Bristol Myers Squibb to Develop a Next-Generation Sequencing Companion Diagnostic to Identify Patients with Homozygous MTAP Deletion

BOSTON--(BUSINESS WIRE)--Foundation Medicine, Inc., a global precision medicine company, today announced an expansion to its collaboration with Bristol Myers Squibb (NYSE: BMY) to develop FoundationOne®CDx as a next-generation sequencing-based companion diagnostic to identify patients with homozygous MTAP deletion in multiple indications for an investigational targeted therapy. The expansion broadens Foundation Medicine’s longstanding relationship in advancing biomarker-driven therapies with Br...

Foundation Medicine to Strengthen Monitoring Portfolio with SAGA Diagnostics’ Tumor-Informed Molecular Residual Disease (MRD) Platform

BOSTON--(BUSINESS WIRE)--Foundation Medicine to expand its monitoring portfolio with SAGA Diagnostics' tumor-informed molecular residual disease platform....
Back to Newsroom